XPR1 Gene Basal Ganglia Calcification Type 6 Idiopathic Genetic Test
At DNA Labs UAE, we offer the XPR1 Gene Basal Ganglia Calcification Type 6 Idiopathic Genetic Test. This test is designed to analyze the XPR1 gene, which is associated with Basal Ganglia Calcification Type 6 (IBGC6), also known as Fahr’s disease.
Test Components and Price
The XPR1 Gene Basal Ganglia Calcification Type 6 Idiopathic Genetic Test is priced at 4400.0 AED. The test can be performed using a blood sample, extracted DNA, or one drop of blood on an FTA card.
Report Delivery and Method
Once the sample is received, the report will be delivered within 3 to 4 weeks. The test utilizes NGS (Next-Generation Sequencing) technology, which allows for the simultaneous analysis of multiple genes.
Test Type and Doctor
The XPR1 Gene Basal Ganglia Calcification Type 6 Idiopathic Genetic Test falls under the category of Dysmorphology. Our team of expert doctors, specializing in Pediatrics, will oversee the test.
Test Department and Pre Test Information
The test is conducted in our Genetics department. Before undergoing the XPR1 Gene Basal Ganglia Calcification Type 6 Idiopathic Genetic Test, it is important to provide the clinical history of the patient. Additionally, a Genetic Counselling session will be conducted to draw a pedigree chart of family members affected by the condition.
Test Details
Basal Ganglia Calcification Type 6 (IBGC6) is a rare genetic disorder characterized by the abnormal accumulation of calcium deposits in the basal ganglia region of the brain. It is also known as Fahr’s disease. NGS genetic testing is used to identify mutations or variations in the XPR1 gene, which may be responsible for the development of this condition.
The term “idiopathic” means that the cause of the disease is unknown. While the exact underlying cause of IBGC6 is still not fully understood, mutations in the XPR1 gene have been identified as a potential cause in some individuals.
The XPR1 Gene Basal Ganglia Calcification Type 6 Idiopathic Genetic Test can help confirm a diagnosis, provide information about the specific genetic mutation involved, and assist in genetic counseling and family planning. It may also aid in the development of targeted treatments or interventions for individuals with this condition.
| Test Name | XPR1 Gene Basal ganglia calcification type 6 idiopathic Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Dysmorphology |
| Doctor | Pediatrics |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for XPR1 Gene Basal ganglia calcification type 6, idiopathic NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with XPR1 Gene Basal ganglia calcification type 6, idiopathic NGS Genetic DNA Test gene XPR1 |
| Test Details |
The XPR1 gene is associated with Basal Ganglia Calcification Type 6 (IBGC6), which is a rare genetic disorder characterized by the abnormal accumulation of calcium deposits in the basal ganglia region of the brain. This condition is also known as Fahr’s disease. NGS (Next-Generation Sequencing) genetic testing refers to a type of genetic testing that uses high-throughput sequencing technologies to analyze multiple genes simultaneously. In the context of IBGC6, NGS genetic testing can be used to identify mutations or variations in the XPR1 gene that may be responsible for the development of the condition. Idiopathic means that the cause of the disease is unknown, and in the case of IBGC6, the exact underlying cause is still not fully understood. However, mutations in the XPR1 gene have been identified as a potential cause of the condition in some individuals. NGS genetic testing for IBGC6 can help in confirming a diagnosis, providing information about the specific genetic mutation involved, and assisting in genetic counseling and family planning. It can also aid in the development of targeted treatments or interventions for individuals with this condition. |
